At Jabez, we strongly believe that the future of cancer therapy will be dominated by strategic combinations. Our mission is to develop highly potent, and clinically practical therapeutics that not only demonstrate superior efficacy as standalone treatments but also create powerful synergies when combined with widely used cancer therapies.
About Jabez
Jabez Biosciences is a clinical-stage biotechnology company that is developing small molecule inhibitors for the treatment of both solid and liquid cancers. Our lead drug candidate, JBZ-001, is a small molecule inhibitor of a crucial enzyme involved in the de novo synthesis of pyrimidine nucleotides, DHODH, that displays highly optimized therapeutic qualities.
Our Pipeline
We are actively pursuing clinical investigations in various solid tumor indications and non-Hodgkin lymphoma (NHL), reflecting our commitment to addressing a broad spectrum of oncological needs. Explore our pipeline to see our current and future plans.
Meet The Jabez Team
At Jabez Biosciences, we’ve assembled a dream team of industry veterans and world-class scientific minds, all united by a singular mission: to develop best-in-class small molecule therapeutics that revolutionize cancer treatment.
Brian Cogley
CFO
Over 15 years leading companies in various industries including life sciences and financial services
